StreetInsider.com News Articles

Form 8-K Medicus Pharma Ltd. For: Sep 04

Fri, 11 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27050861.html

Form 8-K Medicus Pharma Ltd. For: Sep 04

Fri, 11 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27050861.html

Medicus Pharma publishes Phase 2 SkinJect study report

Thu, 10 Sep 2026 07:30:23 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the publication of an abridged Clinical Study Report (CSR) for its SKNJCT-003 trial on ClinicalTrials.gov, identifying the 200 µg SkinJect® patch as the proposed pivotal dose for future development.

The randomized, double-blind, multicenter Phase 2 study enrolled 90 patients across ten U.S. investigative sites, evaluating two dose levels of SkinJect® against a device-only microneedle comparator. All 90 patients completed the study with no treatment discontinuations or withdrawals.

Key conclusions from the CSR include the selection of the 200 µg patch as the lead development dose, adoption of a composite complete response endpoint combining clinical and histological

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Thu, 10 Sep 2026 07:30:00 -0400

CSR provides a clinical foundation for the Company’s recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma

PHILADELPHIA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that an abridged Clinical Study Report (CSR) for SKNJCT-003 (NCT06608238) has been posted on ClinicalTrials.gov, providing transparent public access to the efficacy, safety, drug-delivery and clinical findings from the completed Phase 2 study.

Publication

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Thu, 10 Sep 2026 07:30:00 -0400

Publication

Medicus Pharma shifts focus to CD228V oncology program

Tue, 08 Sep 2026 07:30:56 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) issued a strategic update outlining a shift in its development priorities, with CD228V, a second-generation antibody-drug conjugate (ADC) targeting melanotransferrin/CD228, now designated as the company's principal program.

The company said initial development of CD228V will focus on melanoma, particularly in patients with relapsed or refractory disease. The program is supported by an active U.S. Investigational New Drug (IND) application and a first-in-human Phase 1 clinical study (NCT06799533). CD228V uses Pfizer's vedotin linker-payload platform and targets solid tumors including melanoma, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal cancer.

For its SkinJect® program,

Medicus Pharma shifts focus to CD228V oncology program

Tue, 08 Sep 2026 07:30:56 -0400

For its SkinJect® program,

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Tue, 08 Sep 2026 07:30:00 -0400

Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (“ADC”), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs.

CD228V now

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Tue, 08 Sep 2026 07:30:00 -0400

Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (“ADC”), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs.

CD228V now

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260813/26915646.html

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260813/26915646.html

Form 424B3 Medicus Pharma Ltd.

Thu, 13 Aug 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260813/26915646.html

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 18:00:00 -0400

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion

PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.
During the second

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 18:00:00 -0400

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion

PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.
During the second

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260812/26914349.html

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260812/26914349.html

Form 10-Q Medicus Pharma Ltd. For: Jun 30

Wed, 12 Aug 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260812/26914349.html

Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev

Mon, 03 Aug 2026 07:31:08 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, 2026.
Dr. Mehmud will retain his role as Chief Medical Officer of Medicus and Co-Chairman of Antev's Board of Directors. He succeeds Amit Kohli, who had served as interim CEO of Antev since Medicus completed its acquisition of the company on August 29, 2025. Kohli remained with the company for one year to support the transition of operations, development programs and stakeholder relationships.
Dr. Mehmud holds a medical degree from the University of Cambridge and

Medicus Pharma names Dr. Faisal Mehmud CEO of UK unit Antev

Mon, 03 Aug 2026 07:31:08 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, 2026.
Dr. Mehmud will retain his role as Chief Medical Officer of Medicus and Co-Chairman of Antev's Board of Directors. He succeeds Amit Kohli, who had served as interim CEO of Antev since Medicus completed its acquisition of the company on August 29, 2025. Kohli remained with the company for one year to support the transition of operations, development programs and stakeholder relationships.
Dr. Mehmud holds a medical degree from the University of Cambridge and

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom (“Antev”), the Company’s United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom (“Antev”), the Company’s United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom (“Antev”), the Company’s United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Mon, 03 Aug 2026 07:30:00 -0400

Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom (“Antev”), the Company’s United Kingdom subsidiary, effective August 30, 2026.

Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership

Medicus Pharma gets UAE approval for endometriosis drug study

Fri, 31 Jul 2026 07:30:33 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi has granted investigational new drug authorization for the company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis.
The authorization follows the department's review of the company's chemistry, manufacturing and controls documentation, along with non-clinical, clinical and safety data. The study may proceed subject to completion of site-specific Institutional Review Board and ethics approvals.
PRECISION-E2 is a prospective, randomized, placebo-controlled study designed to enroll approximately 84 women across multiple sites in the UAE. Participants will be divided equally among four treatment

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Fri, 31 Jul 2026 07:30:00 -0400

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health
PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the United Arab Emirates (UAE) Department of Health – Abu Dhabi ("DOH") has granted Investigational New Drug ("IND") authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis, a chronic estrogen-dependent inflammatory disease that affects approximately one